D-0121-2025 Class II Ongoing

Recalled by Viatris Inc — Canonsburg, PA

FDA drug recall D-0121-2025 was initiated by Viatris Inc on Nov 18, 2024 and is designated Class II. Reason for recall: Superpotent Drug and Subpotent Drug: potency failures obtained The recall status is ongoing. Affected quantity: 19, 549 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 18, 2024
Initiation Date
Nov 18, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
19, 549 bottles

Product description

Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90-count bottles (NDC 0378-1817-77) and b) 1000-count bottles (NDC 0378-1817-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Reason for recall

Superpotent Drug and Subpotent Drug: potency failures obtained

Distribution pattern

Nationwide within the United States and Puerto Rico

Code information

Lot #: a) 3192915, 8172108, Exp. Date Mar 2025; b) 3208680, Exp. Date Sep 2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0121-2025
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0121-2025. Report a data issue: hello@regdatalab.com.